Author + information
Drug eluting stents have been used in daily practice since 2002, with clear advantage in reducing the risk of target vessel revascularization, with the impressive reduction of 50% to 70% in restenosis rate. However, the occurrence of late thrombosis could compromise results in the long term, especially if the risk of this event were sustained over the years. In this context, the registry of clinical practice gains special value.
Evaluation of efficacy and safety of drug-eluting stents in the real world.
We report the findings of all patients that underwent percutaneous coronary intervention with a drug eluting stent in the period from January 2002 to April 2007, and followed up for 8 years. Drug eluting stents were used in accordance with the clinical and interventional cardiologist decision and availability of the stent.
A total of 611 patients were included, with clinical follow-up obtained for 96.2% up to 8 years. Total mortality was 8,7%. Non-fatal infarction occurred in 4.3 % of the cases. Target vessel revascularization was 12.4% and the target lesion revascularization 8%. The rate of stent thrombosis was 2.1%. There were no new episodes of stent thrombosis after the fifth year of follow-up. Comparative subanalysis showed no outcome differences between the stents Cypher, Taxus and Endeavor.
These findings indicate that drug eluting stents remain safe and effective at very long term follow-up. Patients in the “real world” may benefit from drug eluting stenting with excellent results in the long-term.